Author name: admin

Uncategorized

New Releases from NCBI BookshelfBehaviour change interventions to promote physical activity in people with intermittent claudication: the OPTIMA systematic review.​Behaviour change interventions to promote physical activity in people with intermittent claudication: the OPTIMA systematic review.

People with intermittent claudication are significantly less active compared to their peers without intermittent claudication, worsening future health outcomes. Supervised

Uncategorized

New Releases from NCBI BookshelfIvacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation.​Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation.

Cystic fibrosis is a life-limiting genetic condition that affects over 9000 people in England. Cystic fibrosis is usually diagnosed through

Uncategorized

New Releases from NCBI BookshelfOlopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Ryaltris): Indication: For the symptomatic treatment of moderate to severe seasonal allergic rhinitis and associated ocular symptoms in adults, adolescents, and children aged 6 years and older: Reimbursement Recommendation [Internet].​Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Ryaltris): Indication: For the symptomatic treatment of moderate to severe seasonal allergic rhinitis and associated ocular symptoms in adults, adolescents, and children aged 6 years and older: Reimbursement Recommendation [Internet].

Canada’s Drug Agency (CDA-AMC) recommends that Ryaltris should not be reimbursed by public drug plans for the symptomatic treatment of

Uncategorized

New Releases from NCBI BookshelfPembrolizumab (Keytruda): Indication: For the treatment of adult patients with resectable stage II, IIIA, or IIIB (T3–4N2) non–small cell lung cancer (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery: Reimbursement Recommendation [Internet].​Pembrolizumab (Keytruda): Indication: For the treatment of adult patients with resectable stage II, IIIA, or IIIB (T3–4N2) non–small cell lung cancer (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment after surgery: Reimbursement Recommendation [Internet].

Canada’s Drug Agency (CDA-AMC) recommends that Keytruda be reimbursed by public drug plans for the treatment of adult patients with

Scroll to Top